Abstract

Background: HIV infection dysregulates the B cell compartment, affecting memory B cell formation and the antibody response to infection and vaccination. Understanding the B cell response to SARS-CoV-2 in people living with HIV (PLWH) may explain the increased morbidity, reduced vaccine efficacy, reduced clearance, and intra-host evolution of SARS-CoV-2 observed in some HIV-1 coinfections.

Methods: We compared B cell responses to COVID-19 in PLWH and HIV negative (HIV-ve) patients in a cohort recruited in Durban, South Africa, during the first pandemic wave in July 2020 using detailed flow cytometry phenotyping of longitudinal samples with markers of B cell maturation, homing and regulatory features.

Results: This revealed a coordinated B cell response to COVID-19 that differed significantly between HIV-ve and PLWH. Memory B cells in PLWH displayed evidence of reduced germinal center (GC) activity, homing capacity and class-switching responses, with increased PD-L1 expression, and decreased Tfh frequency. This was mirrored by increased extrafollicular (EF) activity, with dynamic changes in activated double negative (DN2) and activated naïve B cells, which correlated with anti-RBD-titres in these individuals. An elevated SARS-CoV-2 specific EF response in PLWH was confirmed using viral spike and RBD bait proteins.

Conclusions: Despite similar disease severity, these trends were highest in participants with uncontrolled HIV, implicating HIV in driving these changes. EF B cell responses are rapid but give rise to lower affinity antibodies, less durable long-term memory, and reduced capacity to adapt to new variants. Further work is needed to determine the long-term effects of HIV on SARS-CoV-2 immunity, particularly as new variants emerge.

Funding: This work was supported by a grant from the Wellcome Trust to the Africa Health Research Institute (Wellcome Trust Strategic Core Award [grant number 201433/Z/16/Z]). Additional funding was received from the South African Department of Science and Innovation through the National Research Foundation (South African Research Chairs Initiative, [grant number 64809]), and the Victor Daitz Foundation.

Data availability

All data generated or analyzed during this study are included in the manuscript and Source data 1.

Article and author information

Author details

  1. Robert Krause

    Africa Health Research Institute, Durban, South Africa
    For correspondence
    robert.krause@ahri.org
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1558-0397
  2. Jumari Snyman

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  3. Hwa Shi-Hsia

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  4. Daniel Muema

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  5. Farina Karim

    School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9698-016X
  6. Yashica Ganga

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  7. Abigail Ngoepe

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  8. Yenzekile Zungu

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  9. Inbal Gazy

    KwaZulu-Natal Research Innovation and Sequencing Platform, University of KwaZulu-Natal, Durban, South Africa
    Competing interests
    No competing interests declared.
  10. Mallory Bernstein

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  11. Khadija Khan

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7565-7400
  12. Matilda Mazibuko

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  13. Ntombifuthi Mthabela

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  14. Dirhona Ramjit

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  15. COMMIT-KZN Team

  16. Oliver Limbo

    International AIDS Vaccine Initiative, New York, United States
    Competing interests
    No competing interests declared.
  17. Joseph Jardine

    International AIDS Vaccine Initiative, New York, United States
    Competing interests
    No competing interests declared.
  18. Devin Sok

    International AIDS Vaccine Initiative, New York, United States
    Competing interests
    No competing interests declared.
  19. Ian A Wilson

    Scripps Research Institute, La Jolla, United States
    Competing interests
    No competing interests declared.
  20. Willem Hanekom

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  21. Alex Sigal

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    Alex Sigal, Reviewing editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8571-2004
  22. Henrik Kløverpris

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  23. Thumbi Ndung'u

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2962-3992
  24. Alasdair Leslie

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.

Funding

Wellcome Trust (201433/Z/16/Z)

  • Alex Sigal

National Research Foundation (64809)

  • Alex Sigal

Victor Daitz Foundation

  • Alex Sigal

Max Planck Institute for Infection Biology (open access funding)

  • Alex Sigal

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The study protocol was approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee (approval BREC/00001275/2020). Written informed consent was obtained for all enrolled participants.

Copyright

© 2022, Krause et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 897
    views
  • 193
    downloads
  • 10
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Robert Krause
  2. Jumari Snyman
  3. Hwa Shi-Hsia
  4. Daniel Muema
  5. Farina Karim
  6. Yashica Ganga
  7. Abigail Ngoepe
  8. Yenzekile Zungu
  9. Inbal Gazy
  10. Mallory Bernstein
  11. Khadija Khan
  12. Matilda Mazibuko
  13. Ntombifuthi Mthabela
  14. Dirhona Ramjit
  15. COMMIT-KZN Team
  16. Oliver Limbo
  17. Joseph Jardine
  18. Devin Sok
  19. Ian A Wilson
  20. Willem Hanekom
  21. Alex Sigal
  22. Henrik Kløverpris
  23. Thumbi Ndung'u
  24. Alasdair Leslie
(2022)
HIV skews the SARS-CoV-2 B cell response toward an extrafollicular maturation pathway
eLife 11:e79924.
https://doi.org/10.7554/eLife.79924

Share this article

https://doi.org/10.7554/eLife.79924

Further reading

    1. Epidemiology and Global Health
    2. Genetics and Genomics
    Tianyu Zhao, Hui Li ... Li Chen
    Research Article

    Alzheimer’s disease (AD) is a complex degenerative disease of the central nervous system, and elucidating its pathogenesis remains challenging. In this study, we used the inverse-variance weighted (IVW) model as the major analysis method to perform hypothesis-free Mendelian randomization (MR) analysis on the data from MRC IEU OpenGWAS (18,097 exposure traits and 16 AD outcome traits), and conducted sensitivity analysis with six models, to assess the robustness of the IVW results, to identify various classes of risk or protective factors for AD, early-onset AD, and late-onset AD. We generated 400,274 data entries in total, among which the major analysis method of the IVW model consists of 73,129 records with 4840 exposure traits, which fall into 10 categories: Disease, Medical laboratory science, Imaging, Anthropometric, Treatment, Molecular trait, Gut microbiota, Past history, Family history, and Lifestyle trait. More importantly, a freely accessed online platform called MRAD (https://gwasmrad.com/mrad/) has been developed using the Shiny package with MR analysis results. Additionally, novel potential AD therapeutic targets (CD33, TBCA, VPS29, GNAI3, PSME1) are identified, among which CD33 was positively associated with the main outcome traits of AD, as well as with both EOAD and LOAD. TBCA and VPS29 were negatively associated with the main outcome traits of AD, as well as with both EOAD and LOAD. GNAI3 and PSME1 were negatively associated with the main outcome traits of AD, as well as with LOAD, but had no significant causal association with EOAD. The findings of our research advance our understanding of the etiology of AD.

    1. Epidemiology and Global Health
    Xiaoning Wang, Jinxiang Zhao ... Dong Liu
    Research Article

    Artificially sweetened beverages containing noncaloric monosaccharides were suggested as healthier alternatives to sugar-sweetened beverages. Nevertheless, the potential detrimental effects of these noncaloric monosaccharides on blood vessel function remain inadequately understood. We have established a zebrafish model that exhibits significant excessive angiogenesis induced by high glucose, resembling the hyperangiogenic characteristics observed in proliferative diabetic retinopathy (PDR). Utilizing this model, we observed that glucose and noncaloric monosaccharides could induce excessive formation of blood vessels, especially intersegmental vessels (ISVs). The excessively branched vessels were observed to be formed by ectopic activation of quiescent endothelial cells (ECs) into tip cells. Single-cell transcriptomic sequencing analysis of the ECs in the embryos exposed to high glucose revealed an augmented ratio of capillary ECs, proliferating ECs, and a series of upregulated proangiogenic genes. Further analysis and experiments validated that reduced foxo1a mediated the excessive angiogenesis induced by monosaccharides via upregulating the expression of marcksl1a. This study has provided new evidence showing the negative effects of noncaloric monosaccharides on the vascular system and the underlying mechanisms.